Each month, we analyse key data from the previous month’s concessionary products and the Category M tariff, to create Accord’s ‘Beyond the Headlines’.
This is created as an easy-to-understand summary of the trends that have impacted generic reimbursement, and how the figures fluctuate from one month to the next.
You can read the full version of ‘Beyond the Headlines – September Concessions’ here.
Look out for our next edition, where we will expand our monthly insights to demonstrate the impact Apixaban has had to reimbursement, following a further reduction in Category M tariff for October.
